Pre-eclampsia and Future Cardiovascular Health: An Underused Opportunity to Improve Family Health (FINNCARE)
Background: PE (pre-eclampsia) is a common pregnancy-specific vascular hypertensive disease affecting 3-5% of pregnancies. PE independently increases the risk for premature cardiovascular disease (CVD) in mothers and their offspring long-term. PE provides a unique window for early risk profiling and CVD prevention. However, the efficacy of a family oriented lifestyle intervention to lower CVD risk in families with history of PE has not previously been evaluated.
Aim: This study will explore the impact of PE on CVD progression 8-12 years from delivery in mothers and their children, and assess whether a lifestyle intervention is useful for lowering mother and child blood pressure and improving the CVD risk profile overall in families with a history of PE.
Hypothesis: PE is related with CVD progression mediated by elevated blood pressure. Blood pressure and the CVD risk profile overall is modifiable in mothers and children by a 12-month behavioral lifestyle intervention in families with a history of PE.
Study design: Randomized controlled behavioral lifestyle intervention trial where families (mother, child and father from the FINNPEC study) are offered the opportunity to participate in a lifestyle intervention program 8-12 years after a PE pregnancy. 300 PE families will be randomized 1:1 to a 12-month lifestyle intervention program or to a control group. A parallel group of 100 non-PE control families will be assessed at baseline and follow-up.
Main outcome: 24 hour mean blood pressure change between baseline and follow-up in mother and child.
Significance: This study will provide information on CVD progression in mothers and children 8-12 years from a PE pregnancy. Furthermore, the study assess the effect of a 12-month lifestyle intervention on blood pressure and CVD risk profile overall following a PE pregnancy. Potentially, the study provides the opportunity to identify PE families at highest risk of CVD progression and families amenable to blood pressure and CVD risk profile improvement.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Power analysis:
Power calculations were performed in order to detect 5.5 mmHg reduction in maternal systolic blood pressure with a power of 80% and a 2-sided p-value of 0.05 for the difference between the groups (intervention and control PE) (NICE 2011). Accounting for a 20% loss to follow-up or missing data, a sample of 148 women in the PE intervention group and 148 women in the PE control group is needed.
Specific objectives:
- To assess cardiovascular health and CVD progression in families (mother, child and father) 8-12 years following a PE pregnancy compared with non-PE control families.
- To assess the effectiveness of a behavioral 12-month lifestyle intervention in mothers and their children 8-12 years following a PE pregnancy to lower blood pressure and improve their CVD risk profile overall.
- To assess the effectiveness of a lifestyle intervention on the awareness of CVD risk after a PE pregnancy.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Helsinki, Finlândia, 00029
- Helsinki University Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Families are recruited from the FINNPEC cohort. In FINNPEC, PE was defined as hypertension and proteinuria occurring after 20 weeks gestation (American College of Obstetricians and Gynecologists 2002 criteria). Hypertension was defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg. Proteinuria was defined as urinary excretion of ≥0.3 g protein in a 24-hour specimen, or 0.3 g/L, or two ≥1+ readings on a dipstick in a random urine determination with no evidence of a urinary tract infection. Each PE diagnosis was ascertained based on hospital records and confirmed independently by a research nurse and a study physician in the original FINNPEC case-control study including 1450 nulliparous or multiparous women with a singleton pregnancy with PE and 1065 pregnant control women without PE (aged 18-47 years) from all 5 university hospitals in Finland during 2008-2011.
Exclusion criteria in the FINNPEC: multiple pregnancy, inability to speak Finnish or Swedish.
Exclusion Criteria in the FINNCARE:
- Pregnancy and/or lactation (for all mothers)
- Pre-eclampsia in any previous or subsequent pregnancies (for all non-PE mothers)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: PE intervention
A 12-month lifestyle intervention program to improve mothers and their children blood pressure and CVD risk profile. |
Families are provided at baseline with one 60 min face-to-face dietary counseling session with nutritionist using family-oriented motivational interviewing and solution focusing techniques. The intervention continues in an interactive web-based portal where different modules include assignments, activities, and tests and related videos targeting five cardiovascular health-linked behaviors: 1) improving quality of fat in the diet, 2) increasing the consumption of foods rich in fiber, 3) decreasing the use of salt, 4) increasing physical activity and 5) reducing smoking. |
|
Sem intervenção: PE control
The control group continue habitual lifestyle but will perform the same baseline and follow-up measurements as the intervention group. They will be given general written information on healthy eating. |
|
|
Sem intervenção: Non-PE control
The control group continue habitual lifestyle but will perform the same baseline and follow-up measurements as the intervention group. They will be given general written information on healthy eating. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Blood pressure (mothers)
Prazo: baseline -12 months
|
mean 24 hour ambulatory systolic BP and diastolic BP; mmHg |
baseline -12 months
|
|
Blood pressure (children)
Prazo: baseline -12 months
|
mean 24 hour ambulatory systolic BP and diastolic BP; mmHg |
baseline -12 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Blood pressure 24 hour variability (mothers)
Prazo: baseline -12 months
|
nocturnal systolic and diastolic BP dip; standard deviation of systolic and diastolic BP; weighted standard deviation of systolic and diastolic BP; mmHg |
baseline -12 months
|
|
Arterial stiffness (mothers)
Prazo: baseline -12 months
|
carotid-femoral pulse wave velocity; m/s |
baseline -12 months
|
|
Adiposity BMI (mothers)
Prazo: baseline -12 months
|
BMI; kg/m2 |
baseline -12 months
|
|
Adiposity WHR (mothers)
Prazo: baseline -12 months
|
waist-hip-ratio (no unit) |
baseline -12 months
|
|
Adiposity BF% (mothers)
Prazo: baseline -12 months
|
body fat percentage; % |
baseline -12 months
|
|
Dietary intake FAT (mothers)
Prazo: baseline -12 months
|
food frequency questionnaire on quality of fat (SFA, MUFA and PUFA; E%/day) |
baseline -12 months
|
|
Dietary intake FIBER (mothers)
Prazo: baseline -12 months
|
food frequency questionnaire on fiber intake; g/day |
baseline -12 months
|
|
Dietary intake SALT (mothers)
Prazo: baseline -12 months
|
food frequency questionnaire on salt intake; g/d |
baseline -12 months
|
|
Physical activity and sedentary behavior QUEST1 (mothers)
Prazo: baseline -12 months
|
questionnaire data: weekly number of sessions and minutes of moderate-to-vigorous-intensity physical activity and walking |
baseline -12 months
|
|
Physical activity and sedentary behavior QUEST2 (mothers)
Prazo: baseline -12 months
|
questionnaire data: meeting physical activity recommendations |
baseline -12 months
|
|
Physical activity and sedentary behavior QUEST3 (mothers)
Prazo: baseline -12 months
|
questionnaire data: daily minutes of sitting on a non-weekend and weekend day |
baseline -12 months
|
|
Physical activity and sedentary behavior ACTIVITY1 (mothers)
Prazo: baseline -12 months
|
accelerometer data: daily number of steps |
baseline -12 months
|
|
Physical activity and sedentary behavior ACTIVITY2 (mothers)
Prazo: baseline -12 months
|
accelerometer data: daily minutes of total and intensity-specific physical activity |
baseline -12 months
|
|
Physical activity and sedentary behavior ACTIVITY3 (mothers)
Prazo: baseline -12 months
|
accelerometer data: daily minutes of stationary behavior |
baseline -12 months
|
|
Physical activity and sedentary behavior ACTIVITY4 (mothers)
Prazo: baseline -12 months
|
accelerometer data: daily number of breaks in stationary behavior |
baseline -12 months
|
|
Smoking (mothers)
Prazo: baseline -12 months
|
questionnaire on status of smoking/use of snuf/use of electronic cigarettes/nicotine replacement therapy and number of cigarettes/day |
baseline -12 months
|
|
Laboratory assessment of cardiovascular risk LIPIDS (mothers)
Prazo: baseline -12 months
|
lipids (total cholesterol, LDL, HDL, triglycerides; mmol/l) |
baseline -12 months
|
|
Laboratory assessment of cardiovascular risk INFL (mothers)
Prazo: baseline -12 months
|
hs-CRP; mg/l |
baseline -12 months
|
|
Laboratory assessment of cardiovascular risk HOMA (mothers)
Prazo: baseline -12 months
|
HOMA index calculated as glucose; mmol/l x insulin; mU/l / 22.5 |
baseline -12 months
|
|
Awareness of later life morbidity (mothers)
Prazo: baseline -12 months
|
A brief questionnaire with true or false questions on pre-eclampsia and later life morbidity |
baseline -12 months
|
|
Arterial stiffness (children)
Prazo: baseline -12 months
|
carotid-femoral pulse wave velocity; m/s |
baseline -12 months
|
|
Adiposity BMI (children)
Prazo: baseline -12 months
|
BMI z-score |
baseline -12 months
|
|
Adiposity WHR (children)
Prazo: baseline -12 months
|
waist-hip-ratio (no unit) |
baseline -12 months
|
|
Adiposity BF% (children)
Prazo: baseline -12 months
|
body fat percentage; % |
baseline -12 months
|
|
Dietary intake FFQ (children)
Prazo: baseline -12 months
|
food frequency questionnaire derived data on SFA index, fiber index, salt index (sum of food items rich in SFA/fiber/salt used during the previous week) |
baseline -12 months
|
|
Physical activity and sedentary behavior QUEST1 (children)
Prazo: baseline -12 months
|
questionnaire data: weekly number of days and daily duration of active travel to school and hobbies, structured physical activity outside school hours, unstructured physical activity outside school hours, screen time sitting, non-screen time sitting Accelerometer data: daily number of steps; daily minutes of total and intensity-specific physical activity; daily minutes of and stationary behavior; meeting physical activity recommendations; daily number of breaks in stationary behavior |
baseline -12 months
|
|
Physical activity and sedentary behavior QUEST2 (children)
Prazo: baseline -12 months
|
questionnaire data: weekly number of days and daily duration of active travel to school and hobbies |
baseline -12 months
|
|
Physical activity and sedentary behavior QUEST3 (children)
Prazo: baseline -12 months
|
questionnaire data: structured physical activity outside school hours |
baseline -12 months
|
|
Physical activity and sedentary behavior QUEST4 (children)
Prazo: baseline -12 months
|
questionnaire data: unstructured physical activity outside school hours |
baseline -12 months
|
|
Physical activity and sedentary behavior QUEST5 (children)
Prazo: baseline -12 months
|
questionnaire data: screen time and non-screen time sitting |
baseline -12 months
|
|
Physical activity and sedentary behavior ACTIVITY1 (children)
Prazo: baseline -12 months
|
accelerometer data: daily number of steps |
baseline -12 months
|
|
Physical activity and sedentary behavior ACTIVITY2 (children)
Prazo: baseline -12 months
|
accelerometer data: daily minutes of total and intensity-specific physical activity |
baseline -12 months
|
|
Physical activity and sedentary behavior ACTIVITY3 (children)
Prazo: baseline -12 months
|
accelerometer data: daily minutes of stationary behavior |
baseline -12 months
|
|
Physical activity and sedentary behavior ACTIVITY4 (children)
Prazo: baseline -12 months
|
accelerometer data: meeting physical activity recommendations |
baseline -12 months
|
|
Physical activity and sedentary behavior ACTIVITY5 (children)
Prazo: baseline -12 months
|
accelerometer data: daily number of breaks in stationary behavior |
baseline -12 months
|
|
Laboratory assessment of cardiovascular risk LIPIDS (children)
Prazo: baseline -12 months
|
lipids (total cholesterol, LDL, HDL, triglycerides; mmol/l) |
baseline -12 months
|
|
Laboratory assessment of cardiovascular risk INFL (children)
Prazo: baseline -12 months
|
hs-CRP; mg/l |
baseline -12 months
|
|
Laboratory assessment of cardiovascular risk HOMA (children)
Prazo: baseline -12 months
|
HOMA index calculated as glucose; mmol/l x insulin; mU/l / 22.5 |
baseline -12 months
|
|
Process evaluation: reach1
Prazo: baseline
|
participation rate of the families recruited (research database on study visits) |
baseline
|
|
Process evaluation: reach2
Prazo: baseline
|
representativeness of the families participating (parents' and children's age, questionnaire on socio-economics) |
baseline
|
|
Process evaluation: compliance1
Prazo: baseline -12 months
|
participation rate in measurements (number of study visits and questionnaires completed) |
baseline -12 months
|
|
Process evaluation: compliance2
Prazo: baseline -12 months
|
proportion of sessions completed in the web-based portal (data accumulated in the web-based portal) |
baseline -12 months
|
|
Process evaluation: acceptability1
Prazo: baseline -12 months
|
usefulness and ease of use (questionnaire and proportion of webportal sessions completed by the families) |
baseline -12 months
|
|
Process evaluation: acceptability2
Prazo: baseline -12 months
|
credibility and satisfaction of the web-based portal (questionnaire and proportion of webportal sessions completed by the families) |
baseline -12 months
|
|
Process evaluation: acceptability3
Prazo: baseline -12 months
|
occurrence of technical problems (questionnaire) |
baseline -12 months
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Arterial wall thickness (mothers)
Prazo: baseline
|
intima-media thickness; common carotid, brachial and radial; mm |
baseline
|
|
Left ventricular mass (mothers)
Prazo: baseline
|
left ventricular mass; g |
baseline
|
|
Left ventricular systolic function (mothers)
Prazo: baseline
|
left ventricular global longitudinal strain; % |
baseline
|
|
Left ventricular diastolic function LAV (mothers)
Prazo: baseline
|
left atrial volume; ml |
baseline
|
|
Left ventricular diastolic function MVPWD (mothers)
Prazo: baseline
|
pulsed wave Doppler mitral early to late inflow velocity ratio (no unit) |
baseline
|
|
Left ventricular diastolic function MVlatE (mothers)
Prazo: baseline
|
mitral lateral annular pulsed wave tissue Doppler early velocity; cm/s |
baseline
|
|
Left ventricular diastolic function MVseptE (mothers)
Prazo: baseline
|
septal pulsed wave tissue Doppler early velocity; cm/s |
baseline
|
|
Arterial wall thickness (children)
Prazo: baseline
|
intima-media thickness; common carotid, brachial and radial; mm |
baseline
|
|
Left ventricular mass (children)
Prazo: baseline
|
left ventricular mass; g |
baseline
|
|
Left ventricular systolic function (children)
Prazo: baseline
|
left ventricular global longitudinal strain; % |
baseline
|
|
Left ventricular diastolic function LAV (children)
Prazo: baseline
|
left atrial volume; ml |
baseline
|
|
Left ventricular diastolic function MVPWD (children)
Prazo: baseline
|
pulsed wave Doppler mitral early to late inflow velocity ratio (no unit) |
baseline
|
|
Left ventricular diastolic function MVlatE (children)
Prazo: baseline
|
mitral lateral annular pulsed wave tissue Doppler early velocity; cm/s |
baseline
|
|
Left ventricular diastolic function MVseptE (children)
Prazo: baseline
|
septal pulsed wave tissue Doppler early velocity; cm/s |
baseline
|
|
Heart rate variability (mothers)
Prazo: baseline -12 months
|
standard deviation of all R-R intervals; root mean square of successive R-R interval differences, ms; High frequency power of R-R intervals from spectral band 0.15-0.4 Hz, ms2 ;Low frequency power of R-R intervals from spectral band 0.04-0.15 Hz, ms2 ; and LF/HF ratio |
baseline -12 months
|
|
Blood pressure 24 hour variability (children)
Prazo: baseline -12 months
|
nocturnal systolic and diastolic BP dip; standard deviation of systolic and diastolic BP; weighted standard deviation of systolic and diastolic BP; mmHg |
baseline -12 months
|
|
HRV RR RMS (mothers)
Prazo: baseline - 12 months
|
root mean square of successive R-R interval differences, ms |
baseline - 12 months
|
|
HRV RR HFP (mothers)
Prazo: baseline - 12 months
|
High frequency power of R-R intervals from spectral band 0.15-0.4 Hz, ms2 |
baseline - 12 months
|
|
HRV RR LFP (mothers)
Prazo: baseline - 12 months
|
Low frequency power of R-R intervals from spectral band 0.04-0.15 Hz, ms2 |
baseline - 12 months
|
|
HRV LF/HF ratio (mothers)
Prazo: baseline - 12 months
|
LF/HF ratio |
baseline - 12 months
|
|
HRV RR RMS (children)
Prazo: baseline - 12 months
|
root mean square of successive R-R interval differences, ms |
baseline - 12 months
|
|
HRV RR HFP (children)
Prazo: baseline - 12 months
|
High frequency power of R-R intervals from spectral band 0.15-0.4 Hz, ms2 |
baseline - 12 months
|
|
HRV RR LFP (children)
Prazo: baseline - 12 months
|
Low frequency power of R-R intervals from spectral band 0.04-0.15 Hz, ms2 |
baseline - 12 months
|
|
HRV LF/HF ratio (children)
Prazo: baseline - 12 months
|
LF/HF ratio |
baseline - 12 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Tiina Jääskeläinen, PhD, University of Helsinki
- Cadeira de estudo: Hannele Laivuori, Prof, MD, University of Helsinki and University of Tampere
- Diretor de estudo: Taisto Sarkola, PhD, MD, Helsinki University Central Hospital
Publicações e links úteis
Publicações Gerais
- Jaaskelainen T, Heinonen S, Kajantie E, Kere J, Kivinen K, Pouta A, Laivuori H; FINNPEC Study Group. Cohort profile: the Finnish Genetics of Pre-eclampsia Consortium (FINNPEC). BMJ Open. 2016 Nov 10;6(11):e013148. doi: 10.1136/bmjopen-2016-013148.
- Renlund MA, Jaaskelainen TJ, Kivela ASE, Heinonen ST, Laivuori HM, Sarkola TA. Blood pressure, arterial stiffness, and cardiovascular risk profiles in 8-12-year-old children following preeclampsia (FINNCARE-study). J Hypertens. 2023 Sep 1;41(9):1429-1437. doi: 10.1097/HJH.0000000000003485. Epub 2023 Jun 19.
- Renlund M, Jaaskelainen T, Kivela A, Heinonen S, Laivuori H, Sarkola T. Determinants of vascular structure and function in at-risk children born to mothers managed for pre-eclampsia (FINNCARE study). Front Cardiovasc Med. 2023 Oct 4;10:1264921. doi: 10.3389/fcvm.2023.1264921. eCollection 2023.
- Renlund M, Tulppo MP, Kivela A, Laivuori H, Heinonen S, Jaaskelainen T, Sarkola T. Preeclampsia-exposed children's heart rate variability 8-12 yr after index pregnancy: FINNCARE study. Am J Physiol Heart Circ Physiol. 2024 Jan 1;326(1):H74-H81. doi: 10.1152/ajpheart.00540.2023. Epub 2023 Nov 3.
- Renlund-Vikstrom M, Jaaskelainen TJ, Kivela A, Heinonen S, Laivuori H, Sarkola T. Cardiac Structure and Function in 8- to 12-Year-Old Children Following In-Utero Exposure to Preeclampsia (FINNCARE Study). J Am Heart Assoc. 2024 Aug 6;13(15):e034494. doi: 10.1161/JAHA.124.034494. Epub 2024 Jul 16.
- Kivela A, Renlund-Vikstrom M, Heinonen S, Sarkola T, Laivuori H, Jaaskelainen T. Cardiometabolic health 8-12 years after pre-eclampsia: Role of obesity and gestational diabetes (FINNCARE study). Pregnancy Hypertens. 2025 Sep;41:101226. doi: 10.1016/j.preghy.2025.101226. Epub 2025 Jun 9.
- Jaaskelainen T, Lihtamo A, Meuronen T, Turunen S, Karkkainen O, Kivela A, Renlund-Vikstrom M, Sarkola T, Laivuori H, Heinonen S. Long-term alterations in serum metabolite profiles in women with a history of preeclampsia -FINNCARE study. Sci Rep. 2026 Jul 2. doi: 10.1038/s41598-026-59267-3. Online ahead of print.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- FINNCARE
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .